Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies
about
Effect of Genistein on reproductive parameter and serum nitric oxide levels in morphine-treated miceComparison of a drug versus money and drug versus drug self-administration choice procedure with oxycodone and morphine in opioid addicts.Likeability and abuse liability of commonly prescribed opioids.Extended-release hydrocodone - gift or curse?The opioid rotation ratio of hydrocodone to strong opioids in cancer patientsPersistent pain maintains morphine-seeking behavior after morphine withdrawal through reduced MeCP2 repression of GluA1 in rat central amygdala.Rapid dopamine transmission within the nucleus accumbens: dramatic difference between morphine and oxycodone delivery.Transition from first illicit drug use to first injection drug use among rural Appalachian drug users: a cross-sectional comparison and retrospective survival analysis.Effects of cold pressor pain on the abuse liability of intranasal oxycodone in male and female prescription opioid abusers.Effects of concurrent intravenous morphine sulfate and naltrexone hydrochloride on end-tidal carbon dioxideEffects of repeated oxycodone administration on its analgesic and subjective effects in normal, healthy volunteers.Pharmacodynamic profile of tramadol in humans: influence of naltrexone pretreatmentCore outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendationsDesigning opioids that deter abuseSeparate and combined psychopharmacological effects of alprazolam and oxycodone in healthy volunteers.Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid users.Abuse liability and reinforcing efficacy of oral tramadol in humans.Miotic and subject-rated effects of therapeutic doses of tapentadol, tramadol, and hydromorphone in occasional opioid users.Efficacy of extended-release tramadol for treatment of prescription opioid withdrawal: a two-phase randomized controlled trial.BOLD Imaging in Awake Wild-Type and Mu-Opioid Receptor Knock-Out Mice Reveals On-Target Activation Maps in Response to Oxycodone.Intranasal oxycodone self-administration in non-dependent opioid abusers.The Abuse Potential of Prescription Opioids in Humans-Closing in on the First Century of Research.Perspectives on Intravenous Oxycodone for Control of Postoperative Pain.Abuse Potential and Pharmacodynamic Characteristics of Oral and Intranasal Eluxadoline, a Mixed μ- and κ-Opioid Receptor Agonist and δ-Opioid Receptor Antagonist.Protective effect of crocin on liver toxicity induced by morphine.Who is Overdosing? An Updated Picture of Overdose Deaths From 2008 to 2015.Reduced antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens.Intravenous abuse potential study of oxycodone alone or in combination with naltrexone in nondependent recreational opioid users.Pharmacokinetics and Abuse Potential of Benzhydrocodone, a Novel Prodrug of Hydrocodone, After Intranasal Administration in Recreational Drug Users.Effects of ceftriaxone on hydrocodone seeking behavior and glial glutamate transporters in P rats.
P2860
Q28834110-8396F96B-B4C1-4F00-9E09-8238ED3F2F5FQ33751060-19040E9C-5F55-485E-9130-B9FC0DF72E31Q34300686-805D138D-583F-4C58-9218-118174589992Q34324957-166E74E7-3FE4-430A-BC30-CF5FAFBCCF92Q34458000-7632FDC6-7EDF-4156-A93A-1F0C7BB6BA53Q35117662-CF2D37BA-1720-4165-B303-E51695EC50A0Q35174410-ABD8220C-B2A7-4A4D-8ABA-56BFF22831A3Q35683199-5AC58FCC-226A-4AC1-B88C-33DC5C30E034Q35903378-FADFE103-86B1-43B9-A54B-BA505C6D3333Q35925351-BF33BDF1-28EE-4F3C-8E50-6819CD0CF207Q35927404-5C35747A-224F-465A-BD8E-ABB54066AF19Q36227574-E70C9137-E0CF-4945-9719-A1231A097336Q36389047-651E512A-FC6B-4AD3-803E-6CDDA4A8C0D5Q36415568-91000234-22F7-436D-8F79-69DB0BE43A81Q36599609-9869A433-4A89-4416-8135-2B6A8A8F267DQ36649920-76EC4CAF-32AD-4CD0-89DE-9A0E642C1B17Q36674756-71926243-AD39-4971-AF9B-16A1C295E5D5Q36930408-5E1B8EAF-A58E-4304-BBC9-7DC001BFBE07Q37204912-599C97B2-2947-473D-B3B8-9E353D9E3E30Q37391107-F1746874-751D-4021-8A61-2BD16A5F0D33Q37391604-078466A7-31DD-4DDB-B885-B35ABB71A005Q38379235-6E29CF79-DE7E-46F6-8272-287F5BA53E76Q38590899-18AF430A-CFE2-4B2E-A4D0-983B20A24CBEQ39372153-AAC70EBD-466F-4CEC-9F52-8FBA2682CEB8Q40863023-C8ED2591-31EC-42F1-AEA0-21850DEF93A3Q41664908-AFA398D7-B529-4C94-9E0C-1B550AF4139EQ42954843-7221C91A-A48C-4091-A301-3BB42A06964EQ44337403-6561A942-7AAD-4A18-B72E-9346D1A35769Q50221689-4F81031C-A9DF-4720-B7B9-C010B5BBAD44Q53421512-F5ABA723-DC10-4471-A6A8-2813D1755021
P2860
Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Intravenous oxycodone, hydroco ...... tential and relative potencies
@ast
Intravenous oxycodone, hydroco ...... tential and relative potencies
@en
Intravenous oxycodone, hydroco ...... tential and relative potencies
@nl
type
label
Intravenous oxycodone, hydroco ...... tential and relative potencies
@ast
Intravenous oxycodone, hydroco ...... tential and relative potencies
@en
Intravenous oxycodone, hydroco ...... tential and relative potencies
@nl
prefLabel
Intravenous oxycodone, hydroco ...... tential and relative potencies
@ast
Intravenous oxycodone, hydroco ...... tential and relative potencies
@en
Intravenous oxycodone, hydroco ...... tential and relative potencies
@nl
P2093
P2860
P1433
P1476
Intravenous oxycodone, hydroco ...... tential and relative potencies
@en
P2093
Kevin W Hatton
Michelle R Lofwall
Paul A Nuzzo
Sharon L Walsh
P2860
P2888
P304
P356
10.1007/S00213-010-1942-4
P577
2010-07-28T00:00:00Z
P5875
P6179
1040993654